Glutamine Is Cardioprotective in Patients with Ischemic Heart Disease following Cardiopulmonary Bypass


  • Vladimir V. Lomivorotov
  • Sergey M. Efremov
  • Vladimir A. Shmirev
  • Dmitry N. Ponomarev
  • Vladimir N. Lomivorotov
  • Alexander M. Karaskov



Background: The aim of the present study was to investigate the cardioprotective effects of the perioperative use of N(2)-L-alanyl-L-glutamine (GLN) in patients with ischemic heart disease (IHD) who undergo their operations under cardiopulmonary bypass (CPB).

Methods: This double-blind, placebo-controlled, randomized study included 50 patients who underwent cardiac surgery with CPB. Exclusion criteria were a left ventricular ejection fraction <50%, diabetes mellitus, <3 months since the onset of myocardial infarction, and emergency surgery. Patients in the study group (n = 25) received 0.4 g/kg GLN (Dipeptiven, 20% solution) per day. Patients in the control group (n = 25) were administered a placebo (0.9% NaCl). The primary end point was the dynamics of troponin I at the following stages: (1) prior to anesthesia, (2) 30 minutes after CPB, (3) 6 hours after CPB, (4) 24 hours after surgery, and (5) 48 hours after surgery. Secondary end points included measurements of hemodynamics with a Swan-Ganz catheter.

Results: On the first postoperative day after the surgery, the median troponin I level was significantly lower in the study group than in the placebo group: 1.280 ng/mL (interquartile range [IQR], 0.840-2.230 ng/mL) versus 2.410 ng/mL (IQR, 1.060-6.600 ng/mL) (P = .035). At 4 hours after cardiopulmonary bypass (CPB), the median cardiac index was higher in the patients in the study group: 2.58 L/min per m2 (IQR, 2.34-2.91 L/min per m2) versus 2.03 L/min per m2 (IQR, 1.76-2.32 L/min per m2) (P = .002). The median stroke index also was higher in the patients who received GLN: 32.8 mL/m2 (IQR, 27.8-36.0 mL/m2) versus 26.1 mL/m2 (IQR, 22.6-31.8 mL/m2) (P = .023). The median systemic vascular resistance index was significantly lower in the study group than in the placebo group: 1942 dyn·s/cm5 per m2 (IQR, 1828-2209 dyn·s/cm5 per m2) versus 2456 dyn·s/cm5 per m2 (IQR, 2400-3265 dyn·s/cm5 per m2) (P = .001).

Conclusion: Perioperative administration of GLN during the first 24 hours has cardioprotective effects in IHD patients following CPB. This technique enhances the troponin concentration at 24 hours after surgery and is associated with improved myocardial function.


Engel JM, Mühling J, Kwapisz M, Heidt M. 2009. Glutamine administration in patients undergoing cardiac surgery and the influence on blood glutathione levels. Acta Anaesthesiol Scand 53:1317-23.nHayashi Y, Sawa Y, Fukuyama N, Nakazawa H, Matsuda H. 2002. Preoperative glutamine administration induces heat-shock protein 70 expression and attenuates cardiopulmonary bypass-induced inflammatory response by regulating nitric oxide synthase activity. Circulation 106:2601-7.nKhogali SE, Harper AA, Lyall JA, Rennie MJ. 1998. Effects of l-glutamine on post-ischaemic cardiac function: protection and rescue. J Mol Cell Cardiol 30:819-27.nKhogali SE, Pringle SD, Weryk BV, Rennie MJ. 2002. Is glutamine beneficial in ischemic heart disease? Nutrition 18:123-6.nLiu J, Marchase RB, Chatham JC. 2007. Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. J Mol Cell Cardiol 42:177-85.nLurati Buse GA, Koller MT, Grapow M, Bolliger D, Seeberger M, Filipovic M. 2010. The prognostic value of troponin release after adult cardiac surgery—a metaanalysis. Eur J Cardiothorac Surg 37:399-406.nMcGuinness J, Neilan TG, Cummins R, Sharkasi A, Bouchier-Hayes D, Redmond JM. 2009. Intravenous glutamine enhances COX-2 activity giving cardioprotection. J Surg Res 152:140-7.nMorrison AL, Dinges M, Singleton KD, Odoms K, Wong HR, Wischmeyer PE. 2006. Glutamine's protection against cellular injury is dependent on heat shock factor-1. Am J Physiol Cell Physiol 290:C1625-32.nMurphy E. 2004. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res 94:7-16.nMurphy GJ, Angelini GD. 2004. Side effects of cardiopulmonary bypass: What is the reality? J Card Surg 19:481-8.nOudemans-van Straaten HM, Bosman RJ, Treskes M, van der Spoel HJ, Zandstra DF. 2001. Plasma glutamine depletion and patient outcome in acute ICU admissions. Intensive Care Med 27:84-90.nParry-Billings M, Baigrie RJ, Lamont PM, Morris PJ, Newsholme EA. 1992. Effects of major and minor surgery on plasma glutamine and cytokine levels. Arch Surg 127:1237-40.nRoth E, Funovics J, Muhlbacher F, et al. 1982. Metabolic disorders in severe abdominal sepsis: glutamine deficiency in skeletal muscle. Clin Nutr 1:25-41.nRoth E, Oehler R, Manhart N, et al. 2002. Regulative potential of glutamine— relation to glutathione metabolism. Nutrition 18:217-21.nRoth E. 2008. Nonnutritive effects of glutamine. J Nutr 138:2025S-31S.nSuleiman MS, Moffatt AC, Dihmis WC, et al. 1997. Effect of ischaemia and reperfusion on the intracellular concentration of taurine and glutamine in the hearts of patients undergoing coronary artery surgery. Biochim Biophys Acta 1324:223-31.nTakeda S, Nakanishi K, Ikezaki H, et al. 2002. Cardiac marker responses to coronary artery bypass graft surgery with cardiopulmonary bypass and aortic cross-clamping. J Cardiothorac Vasc Anesth 16:421-5.nVosseller K, Sakabe K, Wells L, Hart GW. 2002. Diverse regulation of protein function by O-GlcNAc: a nuclear and cytoplasmic carbohydrate posttranslational modification. Curr Opin Chem Biol 6:851-7.nWischmeyer PE, Van den Hoek TL, Li C, et al. 2003. Glutamine preserves cardiomyocyte viability and enhances recovery of contractile function after ischemia-reperfusion injury. J Parenter Enteral Nutr 27:116-22.nZar JH. 2010. Biostatistical analysis. Upper Saddle River, NJ: Pearson Prentice-Hall. 960 p.n



How to Cite

Lomivorotov, V. V., Efremov, S. M., Shmirev, V. A., Ponomarev, D. N., Lomivorotov, V. N., & Karaskov, A. M. (2011). Glutamine Is Cardioprotective in Patients with Ischemic Heart Disease following Cardiopulmonary Bypass. The Heart Surgery Forum, 14(6), E384-E388.




Most read articles by the same author(s)